Values First Advisors’s Blueprint Medicines BPMC Stock Holding History

Values First Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,685	Closed	-$729K	–	175
2025 Q2	$729K	Buy	5,685 +652	+13%	+$67.7K	0.4%	76
2025 Q1	$446K	Buy	5,033 +63	+1%	+$6.15K	0.26%	106
2024 Q4	$433K	Buy	4,970 +3,655	+278%	+$335K	0.24%	108
2024 Q3	$122K	Buy	+1,315	New	+$131K	0.07%	172
2023 Q2	–	Sell	-2,618	Closed	-$118K	–	189
2023 Q1	$118K	Buy	+2,618	New	+$118K	0.08%	159

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Values First Advisors's BPMC Position: Q3 2025 in Review

Values First Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 5,685 shares — an estimated $729K sold.

Values First Advisors first reported a position in BPMC in Q1 2023 and held it in 5 quarters. The position peaked at $729K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Values First Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Values First Advisors sold 5,685 Blueprint Medicines shares in Q3 2025, an estimated $729K.
Values First Advisors first reported a position in Blueprint Medicines in Q1 2023 and held it in 5 quarters.
Values First Advisors's Blueprint Medicines position peaked at $729K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Values First Advisors's 13F filing for Q3 2025, filed 21 Oct 2025.